Details of Disease

General Information of Disease (ID: DISNSMNY)

Disease Name	Herpes zoster
Synonyms	postherpetic neuralgia; Zoster; herpes Zoster; shingles; herpes zona
Disease Class	1E91: Zoster
Definition	A common dermal and neurologic disorder caused by reactivation of the varicella-zoster virus that has remained dormant within dorsal root ganglia, often for decades, after the patient's initial exposure to the virus in the form of varicella (chickenpox). It is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area.
Disease Hierarchy	DISV4VFZ: Vesiculobullous skin disease DIS7U38D: Varicella zoster virus infection DISFDJN8: Skin disorder caused by infection DIS8MTAV: Disease arising from reactivation of latent virus DISU6QAV: Post-viral disorder DISEM33Q: Infectious disease DISNSMNY: Herpes zoster
ICD Code	ICD-11 ICD-11: 1E91 ICD-9 ICD-9: 53 Expand ICD-9 53
Disease Identifiers	MONDO ID MONDO_0005609 MESH ID D006562 UMLS CUI C0019360 MedGen ID 42437 SNOMED CT ID 4740000

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
V212	DM4YSMK	Phase 3	Vaccine	[1]
mRNA-1468	DMOZ669	Phase 2	Vaccine	[2]
CRV-101	DM2526O	Phase 1	Vaccine	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 4 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CPS1	TT42M75	moderate	Biomarker	[4]
LRRC32	TT0FAYT	moderate	Genetic Variation	[5]
ARSA	TTYQANR	Strong	Biomarker	[6]
HLA-B	TTGS10J	Strong	Biomarker	[5]
------------------------------------------------------------------------------------

This Disease Is Related to 8 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
FAM110B	OTLYN2T1	moderate	Genetic Variation	[5]
HCP5	OTV0YRI8	moderate	Genetic Variation	[5]
TMC7	OT9RUFN8	moderate	Genetic Variation	[5]
BOD1	OTQL6F4R	Strong	Biomarker	[7]
ENOSF1	OT65D3ZK	Strong	Biomarker	[8]
GP2	OTB6TMGY	Strong	Biomarker	[9]
RECQL4	OT59LSW7	Strong	Biomarker	[8]
TECTA	OT5E0NE2	Strong	Genetic Variation	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 DOT(s)

References

1	ClinicalTrials.gov (NCT01229267) A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001). U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT05701800) A Phase 1/2, Randomized, Observer-Blind, Active-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity and Immunogenicity of mRNA-1468, a Candidate Vaccine to Prevent Herpes Zoster (HZ) in Healthy Adults >=50 Years of Age. U.S.National Institutes of Health.
3	ClinicalTrials.gov (NCT03820414) Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects. U.S. National Institutes of Health.
4	The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis.Vaccine. 2019 May 16;37(22):2896-2909. doi: 10.1016/j.vaccine.2019.04.014. Epub 2019 Apr 11.
5	The eMERGE genotype set of 83,717 subjects imputed to ~40million variants genome wide and association with the herpes zoster medical record phenotype.Genet Epidemiol. 2019 Feb;43(1):63-81. doi: 10.1002/gepi.22167. Epub 2018 Oct 8.
6	The Severity of Herpes Zoster in Inflammatory Bowel Disease Patients Treated With Anti-TNF Agents.Inflamm Bowel Dis. 2018 May 18;24(6):1274-1279. doi: 10.1093/ibd/izx115.
7	Disease burden of varicella versus other vaccine-preventable diseases before introduction of vaccination into the national immunisation programme in the Netherlands.Euro Surveill. 2019 May;24(18):1800363. doi: 10.2807/1560-7917.ES.2019.24.18.1800363.
8	Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review.Phytomedicine. 2019 Jul;60:152905. doi: 10.1016/j.phymed.2019.152905. Epub 2019 Mar 30.
9	B-cell epitopes of varicella-zoster virus glycoprotein II.Arch Virol. 1996;141(12):2465-9. doi: 10.1007/BF01718644.
10	A novel TECTA mutation in a Dutch DFNA8/12 family confirms genotype-phenotype correlation.J Assoc Res Otolaryngol. 2006 Jun;7(2):173-81. doi: 10.1007/s10162-006-0033-z. Epub 2006 Apr 25.